Table 1.
Baseline characteristics before and after propensity score matching.
| Variables | The entire cohort | The PSM cohort | ||||
|---|---|---|---|---|---|---|
| TACE-L (N = 59) | TACE-S (N = 57) | p-value | TACE-L (N = 38) | TACE-S (N = 38) | p-value | |
| Age | 54.05 ± 11.35 | 56.18 ± 12.16 | 0.619 | 55.18 ± 10.94 | 54.39 ± 12.17 | 0.504 |
| Sex | 0.501 | 1.000 | ||||
| Male | 54 (91.5) | 50 (87.7) | 34 (89.5) | 34 (89.5) | ||
| Female | 5 (8.5) | 7 (12.3)) | 4 (10.5) | 4 (10.5) | ||
| Pathogenesis | 0.544 | 0.422 | ||||
| HBV | 54 (91.5) | 49 (86.0) | 36 (94.7) | 34 (89.5) | ||
| HCV | 1 (1.7) | 3 (5.3 | 0 | 3 (7.9) | ||
| Unclear | 4 (6.8) | 5 (8.8) | 2 (5.3) | 1 (2.6) | ||
| PVTT | 0.454 | 0.763 | ||||
| Vp2 | 34 (57.6) | 29 (50.9) | 20 (52.6) | 20 (52.6) | ||
| Vp3 | 16 (27.1) | 17 (29.8) | 11 (28.9) | 13 (34.2) | ||
| Vp4 | 9 (15.3) | 11 (19.3) | 7 (18.4) | 5 (13.2) | ||
| Local Lymphatic metastasis | 0.109 | 1.000 | ||||
| Absent | 45 (76.3) | 50 (87.7) | 32 (84.2) | 32 (84.2) | ||
| Present | 14 (23.7) | 7 (12.3) | 6 (15.8) | 6 (15.8) | ||
| Recurrence | 0.684 | 0.761 | ||||
| Absent | 48 (81.4) | 48 (84.2) | 31 (81.6) | 32 (84.2) | ||
| Present | 11 (10.2) | 9 (15.8) | 7 (18.4) | 6 (15.8) | ||
| TACE times | 2.03 ± 0.118 | 2.09 ± 0.198 | 0.284 | 1.98 ± 0.136 | 2.18 ± 0.25 | 0.612 |
| Size | 0.742 | 0.629 | ||||
| <7 cm | 19 (32.2) | 20 (35.1) | 14 (36.8) | 12 (31.6) | ||
| >7 cm | 40 (67.8) | 37 (64.9) | 24 (63.2) | 26 (68.4) | ||
| Number of Tumor | 0.664 | 0.479 | ||||
| <3 | 36 (61.0) | 37 (64.9) | 22 (57.9) | 25 (65.8) | ||
| ≥3 | 23 (39.0) | 20 (35.1) | 16 (42.1) | 13 (34.2) | ||
| Tumor Location | 0.959 | 1.000 | ||||
| Right Lobe | 34 (57.6) | 32 (56.1) | 19 (50.0) | 20 (52.6) | ||
| Left Lobe | 5 (8.5) | 4 (7.0) | 3 (7.9) | 3 (7.9) | ||
| Both Lobe | 20 (33.9) | 21 (36.8) | 16 (42.1) | 15 (39.5) | ||
| HBV Amplification | 0.122 | 0.788 | ||||
| Absent | 10(16.9) | 14 (24.6) | 7 (18.4) | 8 (21.1) | ||
| Present | 34 (57.6) | 22 (38.6) | 20 (52.6) | 17 (44.7) | ||
| Unknown | 15 (25.4) | 21 (36.8) | 11 (28.9) | 13 (34.2) | ||
| ECOG | 0.804 | 0.446 | ||||
| 0 | 7 (11.9) | 6 (10.5) | 7 (18.4) | 3 (7.9) | ||
| 1 | 35 (59.3) | 34 (59.6) | 20 (52.6) | 24 (63.2) | ||
| 2 | 15 (25.4) | 14 (24.6) | 11 (28.9) | 9 (23.7) | ||
| 3 | 2 (3.4) | 3 (5.3) | 0 | 2 (5.3) | ||
| APT (s) | 0.938 | 1.000 | ||||
| ≤40 | 4 (6.8) | 4 (7.4) | 3 (7.9) | 3 (7.9) | ||
| 40–75,000 | 47 (79.7) | 44 (81.5) | 29 (76.3) | 30 (78.9) | ||
| >75,000 | 8 (13.6) | 6 (11.1) | 6 (15.8) | 5 (13.2) | ||
| Child-Pugh | 0.677 | 1.000 | ||||
| A | 56 (94.9) | 55 (96.5) | 37 (97.4) | 37 (97.4) | ||
| B | 3 (5.1) | 2 (3.5) | 1 (2.6) | 1 (2.6) | ||
| Ascites | 0.235 | 1.000 | ||||
| Absent | 59 (100.0) | 55 (96.4) | 38 (100) | 38 (100.0) | ||
| Present | 0 (0.0) | 2 (3.6) | 0 (0.0) | 0 (0.0) | ||
| AFP (ng/ml) | 0.685 | 0.813 | ||||
| <400 | 26 (44.1) | 23 (40.4) | 14 (36.8) | 15 (39.5) | ||
| ≥400 | 33 (55.9) | 34 (59.6) | 24 (63.2) | 23 (60.5) | ||
| Hemoglobin (g/L) | 138.79 ± 20.58 | 137.53 ± 23.84 | 0.301 | 138.88 ± 2.86 | 141.61 ± 19.73 | 0.845 |
| WBC | 5.96 ± 0.417 | 5.67 ± 0.33 | 0.766 | 5.76 ± 0.33 | 6.16 ± 3.650 | 0.731 |
| PLT | 172.59 ± 13.12 | 159.96 ± 11.04 | 0.662 | 182.85 ± 17.03 | 181.76 ± 99.26 | 0.955 |
| ALT | 50.10 ± 4.05 | 42.94 ± 4.31 | 0.647 | 54.50 ± 5.43 | 47.13 ± 27.85 | 0.572 |
| AST | 71.66 ± 5.95 | 61.02 ± 4.52 | 0.100 | 74.20 ± 8.06 | 65.26 ± 36.24 | 0.422 |
HBV, Hepatitis B virus; HCV, Hepatitis C virus; PVTT, Portal vein tumor thrombus; ECOG, Eastern Cooperative Oncology Group; AFP, Alpha fetoprotein; WBC, White blood cells; PLT, Platelet Count; ALT, Alanine transaminase; AST, Aspartate aminotransferase.